Pharmala Biotech Holdings Inc. Stock Price, News, Quote & History

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions.

Pharmala Biotech Holdings Inc.

Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th

PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists

PharmAla Completes Shipment of LaNeo MDMA to Johns Hopkins

PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand

PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus

PharmAla Completes Import of LaNeo MDMA for US Distribution

PharmAla Incorporates Australian Entity for Clinical Research

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

Top 5 Small-cap Biotech Stocks of 2025

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Latest News

5m @ 13.1g/t Gold Intersected within 20m Mineralised Zone in First Drill Hole to Test New Target at Titan East

Elevra Lithium Limited September 2025 Quarterly Activities Report

$2.48M Capital Raise to Accelerate Drilling at Mt Solitary

Quarterly Activities and Cashflow Report

Quarterly Activities Report and Appendix 5B

Latest News

Outlook Reports world

Featured Biotech Investing Stocks

Browse Companies